The in vitro effects of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone, on rat gastric mucosal eicosanoid synthesis and metabolism

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 55, Issue 3, 1996, Pages 195-200

  Melarange, R ^a   Spangler, R ^b   Hoult, J R S ^c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Smith Kline Beecham Corporation   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 3 AMINO 1 (3 TRIFLUOROMETHYLPHENYL) 2 PYRAZOLINE; 6 METHOXY 2 NAPHTHYLACETIC ACID; AMINOPHENAZONE; ARACHIDONIC ACID; DRUG METABOLITE; INDOMETACIN; LEUKOTRIENE B4; LIPOXYGENASE; NABUMETONE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENIDONE; PROSTAGLANDIN SYNTHASE; SALAZOSULFAPYRIDINE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STOMACH MUCOSA;

ANIMALIA; SIGANUS;

EID: 0029862828     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(96)90098-8     Document Type: Article

References (27)

1. Fries J. F., Williams C. A., Bloch D. A., Michel B. A. Non-steroidalanti-inflammatory drug-associated gastropathy: Incidence and risk factor models. Am J Med 1991; 91: 213-222.
2. Armstrong C. P., Blower A. L. Nonsteroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987; 28: 527-532.
3. Roth S. H. NSAID gastropathy. The central issue. Drugs 1990; 40(suppl 5): 25-28.
4. Greb W. H., Von Schrader H. W., Cerlek S., Dominis M., Hauptman E., Zenic N. Endoscopic studies of nabumetone in patients with rheumatoid arthritis. Am J Med 1987; 83(suppl 4B): 19-24.
5. Lemmel E. M., Stroehmann I. Experience with nabumetone in the treatment of rheumatic conditions - results of an application study in 18 047 patients. Fortschr Med 1988; 106: 63-68.
6. Fleischmann R. The long-term U.S. study - A report on outcome and tolerance. Eur J Inflamm 1991; 11: 50-53.
7. Boyle E. A., Freeman P. C., Mangan F. R., Thomson M. J. Nabumetone (BRL 14777, 4-[6-methoxy-2-naphthyl]-butan-2-one): a new anti-inflammatory agent. J Pharm Pharmacol 1982; 34: 562-569.
8. 1α production and on bile salt-induced changes in gastric mucosal function. J Pharm Pharmacol 1987; 39: 717-720.
9. Melarange R., Gentry C., O'Connell C. et al. Anti-inflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA). Dig Dis Sci 1992; 37: 1847-1852.
10. Robert A. Cytoprotection by prostaglandins. Gastroenterology 1979; 77: 761-767.
11. Melarange R., Gentry C., O'Connell C., Blower P., Toseland N. The anti-inflammatory drug nabumetone lacks the gastrointestinal damaging potential of loxoprofen or naproxen. Jap J Inflamm 1991; 11: 607-614.
12. Melarange R., Gentry C., Durie M., O'Connell C., Blower P. R. Gastrointestinal irritancy, antiinflammatory activity, and prostanoid inhibition in the rat. Differentiation of effects between nabumetone and etodolac. Dig Dis Sci 1994; 39: 601-608.
13. Samuelsson B. Biosynthesis of prostaglandins. Fedn Proc 1972; 31: 1442-1450.
14. Rainsford K. D. The effects of 5-lipoxygenase inhibitors and leukotriene antagonists on the development of gastric lesions induced by non-steroidal anti-inflammatory drugs in mice. Agents Actions 1987; 21: 316-319.
15. Higgs G. A., Flower R. J., Vane J. R. A new approach to anti-inflammatory drugs. Biochem Pharmacol 1979; 28: 1959-1961.
16. Melarange R., Rashbrook L. C. A rat gastric mucosal preparation for studying agents which affect the in vitro production of prostanoids. Prostaglandins Leukot Med 1986; 22: 89-100.
17. Mangan F. R., Flack J. D., Jackson D. Preclinical overview of nabumetone: pharmacology, bioavailability, metabolism, and toxicology. Am J Med 1987; 83(suppl 4B): 6-10.
18. 1α production by indomethacin, aspirin and aminopyrine. Jap J Pharmacol 1989; 49: 483-489.
19. Blackwell G. J., Flower R. J. 1-phenyl-3-pyrazolidone: an inhibitor of cyclo-oxygenase and lipoxygenase pathways in lung and platelets. Prostaglandins 1978; 16: 417-425.
20. Baumann I., Baumann J., Wurm G. Interactions of inhibitors of the lipoxygenase and cyclo-oxygenase pathways with a supplementary binding site on soybean lipoxygenase. Br J Pharmacol 1984; 83: 959-964.
21. Cucurou C., Battioni J. P., Thang D. C., Nam N. H., Mansuy D. Mechanism of inactivation of lipoxygenase by phenidone and BW755C. Biochemistry 1991; 30: 8964-8970.
22. 2 and its subsequent metabolism in rat, rabbit and guinea pig. Biochem Pharmacol 1988; 37: 3591-3599.
23. Jeremy J. Y., Thompson C. S., Mikhailidis D. P., Dandona P. Effect of the antiinflammatory prodrug nabumetone and its principal active metabolite on rat gastric mucosal, aortic and platelet eicosanoid synthesis, in vitro and ex vivo. Prostaglandins Leukot Essent Fatty Acids 1990; 41: 195-199.
24. Flower R. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev 1974; 26: 33-67.
25. Meade E. A., Smith W. L., DeWitt D. L. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other nonsteroidal antiinflammatory drugs. J Biol Chem 1993; 268: 6610-6614.
26. Laneuville O., Breuer D. K., DeWitt D. L., Hla T., Funk C. D., Smith W. L. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 1994; 271: 927-934.
27. Patrignani P., Panara M. R., Greco A. et al. Biochemical and pharmacological characterisation of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994; 271: 1705-1712.